Hyloris Pharmaceuticals SA

Hyloris Reports Full Year Results for 2023 & Provides Business Outlook

14 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

Communication at the request of the FSMA on the transactions with Qliniq

14 Mar 2024 01:59:00 By Nasdaq GlobeNewswire

Hyloris to Report 2023 Full-Year Results on 14 March 2024

08 Mar 2024 01:00:00 By Nasdaq GlobeNewswire

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada

27 Feb 2024 12:00:00 By Nasdaq GlobeNewswire

Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

14 Feb 2024 12:00:00 By Nasdaq GlobeNewswire

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

30 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)

18 Jan 2024 13:00:00 By Nasdaq GlobeNewswire

Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)

16 Jan 2024 13:30:00 By Nasdaq GlobeNewswire

Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)

26 Dec 2023 12:00:09 By Nasdaq GlobeNewswire

Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome

21 Dec 2023 12:30:00 By Nasdaq GlobeNewswire

Hyloris announces US FDA approval for Podofilox Gel

04 Dec 2023 01:00:00 By Nasdaq GlobeNewswire

Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada

24 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Hyloris announces U.S. FDA Approval of Maxigesic® IV

18 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook

06 Sep 2023 16:00:00 By Nasdaq GlobeNewswire

Hyloris announces enrolment of first patient in a 4-arm clinical trial of Alenura(TM)

22 Jun 2023 01:00:00 By Nasdaq GlobeNewswire

Hyloris shareholders approve all resolutions at the Annual General Meeting

13 Jun 2023 11:59:00 By Nasdaq GlobeNewswire

Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region

08 Jun 2023 11:59:00 By Nasdaq GlobeNewswire

Hyloris announces potential registration date for Maxigesic® IV in the US

02 May 2023 01:00:00 By Nasdaq GlobeNewswire

Hyloris releases Annual Report 2022, including ESG objectives

28 Apr 2023 01:00:00 By Nasdaq GlobeNewswire

Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA

18 Apr 2023 01:00:00 By Nasdaq GlobeNewswire